体内研究 (In Vivo) |
Triphenyl phosphate (5-50 mg/kg;口服;每日;连续 30 天) 会在 C57BL/6 J 小鼠中诱导剂量依赖性心脏毒性,其中 50 mg/kg 剂量会引发显著的心脏纤维化、氧化应激、线粒体功能障碍、线粒体自噬及心肌细胞凋亡。 Triphenyl phosphate (0.5-2 mg/kg;口服;每日;妊娠第 0 天至第 12 天) 可诱导妊娠 C57BL/6 小鼠的胎盘氧化应激,激活炎症因子并扰乱色氨酸代谢。 Triphenyl phosphate (1-150 mg/kg;口服;每日一次;连续 60 天) 可诱导性别特异性脂质代谢紊乱,并通过剂量依赖性地增加腹股沟脂肪组织系数、促进脂肪细胞肥大以及上调成脂和脂质代谢相关基因,促进雄性小鼠肥胖,但对雌性小鼠的脂肪组织形态无显著影响。 Triphenyl phosphate (1-500 μg/L;暴露于钾溶液;72 h) 可通过破坏 JNK 信号通路在秀丽隐杆线虫中诱导浓度依赖性生殖毒性。 Triphenyl phosphate (0.89-9.19 μg/kg;口服;每日一次;28 周) 通过破坏肠-脑轴诱导雌性 BALB/c 小鼠出现显著的焦虑样和抑郁样行为,包括肠道菌群失调、全身氧化应激与炎症反应,以及前额叶皮层代谢和信号通路紊乱。
| Animal Model: |
C57BL/6 J (adult male, 20-25 g) |
| Dosage: |
5 mg/kg; 50 mg/kg |
| Administration: |
p.o.; daily; 30 days |
| Result: |
Induced disordered myocardial cell arrangement and increased eosinophilic cardiomyocytes at 50 mg/kg. Elevated serum creatine kinase isoenzymes (CK-MB) and lactate dehydrogenase (LDH) levels significantly at 50 mg/kg. Increased heart malondialdehyde (MDA) levels, while decreased superoxide dismutase (SOD) and serum glutathione peroxidase (GSH-Px) activities at 50 mg/kg. Caused irregular cardiomyocyte mitochondrial shapes and disordered cristae at 50 mg/kg. Decreased protein expression of mitochondrial fusion/fission factors (Mfn1, Mfn2, Opa1, Drp1, Fis1) significantly at 50 mg/kg. Induced autophagosomes in cardiomyocytes, with increased protein expression of Parkin, Pink1, and LC3II/I at 50 mg/kg. Increased TUNEL-positive apoptotic cardiomyocytes at 50 mg/kg. Increased protein expression of Bax, CytC, and Cleaved-Caspase 3, decreased Bcl-2 expression, and increased Cleaved-Caspase 9 expression at 50 mg/kg. Increased cardiac collagen deposition, with increased protein expression of Wnt, β-catenin, p-β-catenin, collagen I, collagen III, CTGF, and fibronectin at 50 mg/kg. Showed no significant changes in myocardial histopathology, serum CK-MB/LDH levels, oxidative stress markers, mitochondrial structure/factor expression, or cardiac fibrosis markers at 5 mg/kg. Increased Cleaved-Caspase 9 protein expression significantly, with no change in TUNEL-positive apoptotic cells at 5 mg/kg. |
| Animal Model: |
C57BL/6 (6-8 weeks old, female, pregnant) |
| Dosage: |
0.5 mg/kg; 1 mg/kg; 2 mg/kg |
| Administration: |
p.o.; daily; E0 to E12 |
| Result: |
Increased placental GSH to ~100 μmol/g, MDA to ~4 nmol/mgprot, and SOD vitality to ~150 U/mgprot at 2 mg/kg. Increased placental MDA to ~3 nmol/mgprot and decreased SOD vitality to ~100 U/mgprot at 1 mg/kg. Increased placental NFκB, IL6, MAOA, and KYNU gene expression, and decreased TPH1 and DDC gene expression at 0.5 mg/kg. Increased placental NFκB, TNFα, IL6, MAOA, KYNU, and IDO1 gene expression, and decreased TPH1 and DDC gene expression at 1 mg/kg. Increased placental NFκB, TNFα, IL6, MAOA, KMO, and KYNU gene expression, and decreased TPH1 and DDC gene expression at 2 mg/kg. Increased placental NFκB, IDO1, and MAOA protein expression, and decreased TPH1 protein expression at 0.5 mg/kg. Increased placental NFκB, TNFα, IL6, IDO1, TDO2, and MAOA protein expression, and decreased TPH1 protein expression at 1 mg/kg. Increased placental NFκB, TNFα, IL6, IDO1, TDO2, and MAOA protein expression, and decreased TPH1 protein expression at 2 mg/kg. Decreased placental tryptophan to ~25 μg/g FW and 5-HTP to ~0.015 μg/g FW at 1 mg/kg. Increased placental serotonin to ~0.15 μg/g FW, 5-HIAA to ~0.3 μg/g FW, and KYN to ~25 μg/g FW at 1 mg/kg. Showed a trend toward increased 3-HK levels at 1 mg/kg. |
| Animal Model: |
BALB/c (male, female, 3 weeks old at study start, oral exposure to triphenyl phosphate for 60 days to induce lipid metabolism disorder) |
| Dosage: |
1 mg/kg/day; 10 mg/kg/day; 150 mg/kg/day |
| Administration: |
p.o.; daily; 60 days |
| Result: |
Increased inguinal adipose tissue coefficient in a dose-dependent manner in male mice. Induced significant adipocyte hypertrophy across all doses in male mice, with mean adipocyte area significantly larger than control. Increased serum total cholesterol (TC) and high-density lipoprotein cholesterol (HDL-C) levels in male mice treated with 150 mg/kg/day, while all doses reduced serum triglyceride (TG) levels in male mice. Upregulated PPARγ mRNA expression in a dose-dependent manner in male mice. Upregulated chemerin mRNA expression in male mice treated with 150 mg/kg/day. Upregulated lipid synthesis-related genes (Pck1, PDK, ChERBP) and lipolytic genes (Lipe, MGL) in male mice. Showed an upward trend in serum TG, TC, HDL-C, and low-density lipoprotein cholesterol (LDL-C) levels in female mice treated with 150 mg/kg/day, with no significant changes in inguinal adipose tissue coefficient or adipocyte size compared to control. |
| Animal Model: |
wild-type Bristol N2; MT1079/egl-15 (n484) X; VC1089/mkk-4 (ok1545) X; VC822/kgb-2 (gk361) IV; JT366/vhp-1(sa366) II (synchronized L1-stage larvae) |
| Dosage: |
1 μg/L, 10 μg/L, 100 μg/L, 500 μg/L |
| Administration: |
exposure in K+ solution; daily feeding; 72 hours |
| Result: |
Reduced mean lifespan by 1.65% (1 μg/L), 12.47% (10 μg/L), 13.3% (100 μg/L), and 25.22% (500 μg/L) relative to controls. Determined 10-day LC50 as 575.47 μg/L (95% CI: 450.58-819.39 μg/L). Reduced germ cell counts in the mitotic zone, transition zone, and meiotic prophase by 37.5%/41.0% (1 μg/L/500 μg/L), 30.2%/28.9%, and 36.9%/38.5% respectively. Increased gonadal apoptotic cell count by 17.2% (1 μg/L), 77.6% (10 μg/L), 133.2% (100 μg/L), and 138.9% (500 μg/L) relative to controls. Reduced uterine embryo count by 14.2% (1 μg/L), 18.2% (10 μg/L), 18.1% (100 μg/L), and 21.8% (500 μg/L) relative to controls. Reduced total progeny count by 10.66% (1 μg/L), 13.94% (10 μg/L), 15.25% (100 μg/L), and 17.39% (500 μg/L) relative to controls. Downregulated transcript levels of egl-15, dlk-1, mkk-4, kgb-2, and vhp-1, while upregulated kgb-1 in 500 μg/L exposed wild-type worms. Increased gonadal apoptotic cell counts significantly higher than in exposed wild-type worms, and reduced uterine embryo counts and total progeny counts significantly lower than in exposed wild-type worms in mutant strains exposed to 1 μg/L or 500 μg/L TPHP. |
| Animal Model: |
BALB/c (female, 3 weeks old, 15−18 g) |
| Dosage: |
0.89 μg/kg/day; 9.19 μg/kg/day |
| Administration: |
p.o.; daily; 28 weeks |
| Result: |
Reduced distance traveled in the central area by 67.8%, reduced time spent moving in the central area by 64.1%, significantly reduced upright behavior count, and significantly reduced grooming behavior count (9.19 μg/kg/day, open field test). Reduced open arm entry frequency by 2.1-fold, reduced open arm retention time by 84.1% (9.19 μg/kg/day, elevated plus maze test). Reduced sucrose preference index by 40.1% (9.19 μg/kg/day, sucrose preference test). Reduced uric acid levels, reduced 5-hydroxytryptophan levels, elevated quinolinic acid levels, elevated glutamate levels, significantly elevated reactive oxygen species, nitric oxide, and malondialdehyde levels, upregulated catalase and superoxide dismutase expression, and increased NF-κB p65 and pro-inflammatory factors (TNF-α, IL-1β, IL-6) (9.19 μg/kg/day, prefrontal cortex). Decreased relative abundance of Bacteroidota, increased Firmicutes, significantly reduced relative abundance of norank_f_Muribaculaceae, Lactobacillus, Alloprevotella, Bacteroides, and g_Akkermansia, significantly increased Lachnospiraceae_NK4A136_group, significantly increased Chao1 index, and showed β-diversity compositional differences from controls (9.19 μg/kg/day, gut microbiota). Reduced xanthine levels, elevated uric acid levels, reduced 5-hydroxytryptophan levels, and significantly reduced acetic acid, propionic acid, and butyric acid levels. Significantly upregulated quinolinic acid and glutamate levels, significantly downregulated xanthine, 5-hydroxytryptophan, acetic acid, propionic acid, and butyric acid levels, significantly elevated reactive oxygen species, nitric oxide, malondialdehyde, TNF-α, IL-1β, IL-6, and NF-κB p65 levels, and reached a mean level of 2.09 ng/mL (9.19 μg/kg/day, serum). Significantly reduced time spent moving in the central area and reduced upright behavior count (0.89 μg/kg/day, open field test). Showed 1208 upregulated and 1382 downregulated genes relative to controls, altered NF-κB signaling pathway and leukocyte transendothelial migration pathways, and disrupted purine and tryptophan metabolism pathways with trends matching the high-dose group (0.89 μg/kg/day, prefrontal cortex). Mirrored high-dose group trends but most changes were not statistically significant (0.89 μg/kg/day, gut microbiota). Reached a mean level of 0.36 ng/mL (0.89 μg/kg/day, serum). |
|